SYSQUAN

System-wide Quantitation of the Human Proteome

SYSQUAN

Transforming proteomics research: No competing product can offer the same results. A technology that can solve the serious reproducibility crisis at a low cost.

Technology

The human and mouse proteome are remarkably similar

 

The ability to generate proteome-wide quantitative data that is truly comparable across laboratories and studies will entirely transform biomedical/clinical research. The proposed method (SysQuan) for system-wide quantitation of the human proteome will minimize the cost and analysis time of multiplexed and precise absolute protein quantitation using LC-MS and stable isotope labelled (SIL) mouse (mice fed 13Lys6-labelled feed) to generate the internal standards. SysQuan technology based on the labelled mouse proteome relies on the fact that 76% of all human proteins share unique tryptic peptides with mouse, and >132k unique tryptic human peptides (no missed cleavages, 7-25 amino acids, containing one Lys residue) are shared with mouse.
Technological Advantages

Five striking advantages of SysQuan over conventional MS-based quantitation strategies

  • Expensive synthetic SIS peptides are made obsolete
  • The method permits absolute quantitation of 1000s of peptides within one LC-MS run
  • Measuring several peptides per protein increases the confidence of the assay
  • The method accounts of variations in both digestion efficiency (since labelled proteins are added instead of labelled peptides) and matrix effects (lysate of the same organ/biofluid from the labelled mouse is added to the human sample)
  • The method enables both targeted and non-targeted absolute quantitation

Five striking advantages of SysQuan over conventional MS-based quantitation strategies

  • Expensive synthetic SIS peptides are made obsolete
  • The method permits absolute quantitation of 1000s of peptides within one LC-MS run
  • Measuring several peptides per protein increases the confidence of the assay
  • The method accounts of variations in both digestion efficiency (since labelled proteins are added instead of labelled peptides) and matrix effects (lysate of the same organ/biofluid from the labelled mouse is added to the human sample)
  • The method enables both targeted and non-targeted absolute quantitation
APPLICATIONS

SysQuan will transform large-scale health-related research projects by dramatically lowering the cost of large-scale and population-wide testing and screening. To understand disease and to identify earlier markers of disease, cohorts with 1,ooo-10,000s of samples need to be analysed. While this is routine for genomics and also transcriptomics, the more phenotypic readout of the proteome is massively hindered by the high cost and low-throughput of MS technologies and the limitations of aptamer/antibody-based technologies (mainly relative quantitation, absolute quantitation only in a few cases, low specificity, high false positive rate).

With sysQuan this will change, paving the way for low-cost population-wide absolute quantitative proteomics in a standardized fashion. This will undoubtedly lead to the identification of early (or earlier) markers of disease which will improve treatment outcomes. It can also be used to compare responses to different drugs, thus not only helping to prevent disease progression, but also to improve the treatment of diseases.
PRODUCTS

MRMP will develop it’s first commercial sysQuan product ­the first in a projected series of kits — utilizing this new technology. We envision a new series of sysQuan kits designed for the analysis of different human tissues, including heart (sysQuanH), lung (sysQuanlu), liver,(sysQuanLi)